A Better Vaccine is Needed
Our NasoShield product candidate has the potential to be an important next generation vaccine for the prevention of anthrax disease following inhalation of pathogen spores. The only FDA-approved vaccine for anthrax requires multiple injections over six months before sufficient immunity to anthrax is developed and can be associated with discomfort following injection.
Key Advantages of NasoShield
Our NasoShield product candidate is being developed using our RespirVec technology to stimulate the immune system with a single intranasal administration as opposed to multiple injections. Based on head-to-head results from studies performed in gold-standard preclinical models, NasoShield provided more rapid and consistent protection when compared to the currently approved anthrax vaccine, both potential key advantages for presumed use in a bioterrorism emergency.
The NasoShield anthrax vaccine is being developed with the support of the Biomedical Advanced Research and Development Authority, a branch of the United States Department of Health and Human Services.